Vertex Common Stock Total Equity from 2010 to 2024

VRTX Stock  USD 483.04  2.49  0.51%   
Vertex Pharmaceuticals Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity will likely drop to about 1.9 M in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
1999-09-30
Previous Quarter
2.6 M
Current Value
2.6 M
Quarterly Volatility
771.6 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.3 B, Gross Profit of 9 B or Other Operating Expenses of 6.4 B, as well as many indicators such as Price To Sales Ratio of 10.12, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Vertex Pharmaceuticals over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Vertex Pharmaceuticals' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Vertex Common Stock Total Equity Regression Statistics

Arithmetic Mean2,291,777
Geometric Mean2,106,246
Coefficient Of Variation26.43
Mean Deviation361,128
Median2,450,000
Standard Deviation605,676
Sample Variance366.8B
Range2.7M
R-Value0.55
Mean Square Error273.8B
R-Squared0.31
Significance0.03
Slope75,031
Total Sum of Squares5.1T

Vertex Common Stock Total Equity History

20241.9 M
2023M
20222.6 M
20212.5 M
20202.6 M
20192.6 M
20182.5 M

About Vertex Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Vertex Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Vertex Pharmaceuticals investors use historical funamental indicators, such as Vertex Pharmaceuticals's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Vertex Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Vertex Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vertex Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vertex Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total EquityM1.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.